Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial

References

• European Medicines Agency: EMA/697484/2018 – Elebrato Ellipta. Available from: https://www.ema.europa.eu/en/documents/overview/elebrato-ellipta-epar-medicine-overview_en.pdf. Accessed November 30, 2023.
   Google Scholar
• European Medicines Agency: EMA/229136/2019 – Trimbow. Available from: https://www.ema.europa.eu/en/documents/overview/trimbow-epar-medicine-overview_en.pdf. Accessed November 30, 2023.
   Google Scholar
• European Medicines Agency: EMA/561272/2020 – Trixeo Aerosphere. Available from: https://www.ema.europa.eu/en/documents/overview/trixeo-aerosphere-epar-medicine-overview_en.pdf. Accessed November 30, 2023.
   Google Scholar
• Zhang S, King D, Rosen VM, Ismaila AS. Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: a Systematic Literature Review. Int J Chron Obstruct Pulmon Dis. 2020;15:417–438. doi:10.2147/COPD.S234823
   PubMed Web of Science ®Google Scholar
• Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481–1490.
   PubMed Web of Science ®Google Scholar
• Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie COPD – Leitlinienreport, 2. Auflage. Version 1; 2021. Available from: www.leitlinien.de/copd. Accessed November 30, 2023.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2023 update. Available from: https://goldcopd.org/2023-gold-report-2/. Accessed November 30, 2023.
   Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi:10.1183/13993003.00164-2019
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC
   PubMed Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. doi:10.1164/rccm.201911-2207OC
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Ismaila AS, Haeussler K, Czira A, et al. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: a Network Meta-Analysis. Adv Ther. 2022;39(9):3957–3978. doi:10.1007/s12325-022-02231-0
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Worsley S, Ismaila AS, et al. INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Research. 2021;7(2). doi:10.1183/23120541.00950-2020
   Google Scholar
• Halpin DM, Kerkhof M, Soriano JB, Mikkelsen H, Price DB. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir Res. 2016;17(1):120. doi:10.1186/s12931-016-0433-5
   PubMed Web of Science ®Google Scholar
• Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2009;10():37. doi:10.1186/1745-6215-10-37
   PubMed Web of Science ®Google Scholar
• Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. N Engl J Med. 2016;375(13):1253–1260. doi:10.1056/NEJMoa1608033
   PubMed Web of Science ®Google Scholar
• Heddini A, Sundh J, Ekström M, Janson C. Effectiveness trials: critical data to help understand how respiratory medicines really work? Eur Clinical Respir J. 2019;6(1):1565804. doi:10.1080/20018525.2019.1565804
   PubMed Web of Science ®Google Scholar
• Pate A, Barrowman M, Webb D, et al. Study investigating the generalisability of a COPD trial based in primary care (Salford Lung Study) and the presence of a Hawthorne effect. BMJ Open Respir Res. 2018;5(1):e000339. doi:10.1136/bmjresp-2018-000339
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Plaza V, Fernández-Rodríguez C, Melero C, et al. Validation of the ‘Test of the Adherence to Inhalers’ (TAI) for Asthma and COPD Patients. J Aerosol Med Pulm Drug Deliv. 2016;29(2):142–152. doi:10.1089/jamp.2015.1212
   PubMed Web of Science ®Google Scholar
• Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203. doi:10.1016/S2213-2600(14)70001-3
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–344. doi:10.1016/S2213-2600(18)30102-4
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-8
   PubMed Web of Science ®Google Scholar
• Halpin DM, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017;12:2891–2908. doi:10.2147/COPD.S139470
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Kunisaki KM, Strand MJ, et al. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;195(3):324–330. doi:10.1164/rccm.201605-1014OC
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Smeeth L, Quint JK. Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practice-based Population with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018;198(4):464–471. doi:10.1164/rccm.201710-2029OC
   PubMed Web of Science ®Google Scholar
• Del Pinto R, Giua C, Keber E, Grippa E, Tilotta M, Ferri C. Impact of 2021 ESC Guidelines for Cardiovascular Disease Prevention on Hypertensive Patients Risk: secondary Analysis of Save Your Heart Study. High Blood Press Cardiovasc Prev. 2023;30(2):167–173. doi:10.1007/s40292-023-00568-3
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925–1966. doi:10.1007/s00125-022-05787-2
   PubMed Web of Science ®Google Scholar
• Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44. doi:10.1007/s00198-018-4704-5
   PubMed Web of Science ®Google Scholar
• Singh D, Hurst JR, Martinez FJ, et al. Predictive modeling of COPD exacerbation rates using baseline risk factors. Ther Adv Respir Dis. 2022;16:17534666221107314. doi:10.1177/17534666221107314
   Web of Science ®Google Scholar
• Singh D, Criner GJ, Dransfield MT, et al. InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. Respir Res. 2021;22(1):130. doi:10.1186/s12931-021-01706-y
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Celli BR, Locantore N, Yates J, et al. Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2012;185(10):1065–1072. doi:10.1164/rccm.201110-1792OC
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. doi:10.1016/S0140-6736(16)30069-1
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa1516385
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Alqahtani JS, Oyelade T, Aldhahir AM, et al. Reduction in hospitalised COPD exacerbations during COVID-19: a systematic review and meta-analysis. PLoS One. 2021;16(8):e0255659. doi:10.1371/journal.pone.0255659
   PubMed Web of Science ®Google Scholar
• Dezman ZDW, Stryckman B, Zachrison KS, et al. Masking for COVID-19 Is Associated with Decreased Emergency Department Utilization for Non-COVID Viral Illnesses and Respiratory Conditions in Maryland. Am J Med. 2021;134(10):1247–1251. doi:10.1016/j.amjmed.2021.06.008
   PubMed Web of Science ®Google Scholar
• Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal Clinically Important Differences in Pharmacological Trials. Am J Respir Crit Care Med. 2014;189(3):250–255. doi:10.1164/rccm.201310-1863PP
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416–469. doi:10.1183/09031936.00099306
   PubMed Web of Science ®Google Scholar
• Maltais F, Ferguson GT, Feldman GJ, et al. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD. Adv Ther. 2019;36(9):2434–2449. doi:10.1007/s12325-019-01015-3
   PubMed Web of Science ®Google Scholar
• Feldman GJ, Sousa AR, Lipson DA, et al. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: a Randomized Study. Adv Ther. 2017;34(11):2518–2533. doi:10.1007/s12325-017-0626-4
   PubMed Web of Science ®Google Scholar
• Gessner C, Trinkmann F, Bahari Javan S, et al. Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany - The TriOptimize Study. Int J Chron Obstruct Pulmon Dis. 2022;17:3019–3031. doi:10.2147/COPD.S382405
   PubMed Web of Science ®Google Scholar
• Sciurba F, Rennard SI. Rationale for a redundant formulary. The Hawthorne effect and the art of medicine. Am J Respir Crit Care Med. 2015;191(11):1224–1225. doi:10.1164/rccm.201503-0496ED
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DG. Regression towards the mean. BMJ. 1994;308(6942):1499. doi:10.1136/bmj.308.6942.1499
   PubMed Web of Science ®Google Scholar
• Plate T, Friedrich FW, Beier J. Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study. Int J Chron Obstruct Pulmon Dis. 2020;15:1335–1347. doi:10.2147/COPD.S252354
   PubMed Web of Science ®Google Scholar